Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 18/20 | 0.53 |
| ▸ | SYK | P43405 | 2/20 | 0.52 |
| ▸ | ROCK1 | Q13464 | 9/20 | 0.51 |
| ▸ | CLK2 | P49760 | 1/20 | 0.47 |
| ▸ | BLK | P51451 | 1/20 | 0.47 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.47 |
| ▸ | STK3 | Q13188 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.47 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7077410 | 0.91 | SYK (0.52) | ROCK2SYKROCK1CLK2DYRK1A | |
| SCHEMBL7078494 | 0.85 | ROCK2 (0.53) | ROCK2SYKROCK1CLK2BLK | |
| SCHEMBL7077582 | 0.85 | SYK (0.47) | ROCK2SYKROCK1CLK2BLK | |
| SCHEMBL7079063 | 0.81 | ROCK2 (0.55) | ROCK2ROCK1 | |
| SCHEMBL7081266 | 0.80 | RPS6KB1 (0.51) | ROCK2SYKROCK1 | |
| SCHEMBL7081263 | 0.80 | RPS6KB1 (0.51) | ROCK2SYKROCK1 | |
| SCHEMBL7077421 | 0.79 | ROCK2 (0.55) | ROCK2SYKROCK1 | |
| SCHEMBL7081452 | 0.79 | SYK (0.50) | SYKCLK2STK3DYRK1ACLK4 | |
| SCHEMBL7081412 | 0.78 | ALDH1A1 (0.48) | ROCK2ROCK1CLK2CSNK2A1DYRK1A | |
| SCHEMBL7077576 | 0.76 | ROCK1 (0.55) | ROCK2SYKROCK1CLK2BLK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6608058-B2 | Therapeutic composition for hepatitis B, hepatitis C, or acquired immune deficiency syndrome | DONG WHA PHARM. IND. CO., LTD. (KR) | 2003-08-19 | — | — | US | claimed |
| US-20030092709-A1 | 6-Methylnicotinamide derivatives as antiviral agents | DONG WHA PHARM. CO., LTD. (KR) | 2003-05-15 | — | — | US | claimed |
| US-6608058-B2 | Therapeutic composition for hepatitis B, hepatitis C, or acquired immune deficiency syndrome | DONG WHA PHARM. IND. CO., LTD. (KR) | 2003-08-19 | — | — | US | disclosed |
| US-20030092709-A1 | 6-Methylnicotinamide derivatives as antiviral agents | DONG WHA PHARM. CO., LTD. (KR) | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092709-A1 | 6-Methylnicotinamide derivatives as antiviral agents | TPMT, HAVCR2, NNMT | ROCK2 4018/4885SYK 4369/4885ROCK1 3803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.